Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) treats a variety of malignant and nonmalignant hematological conditions. 1 HSCT initially was restricted to patients with satisfactory organ functions due to the very high morbidity of myeloablative transplants. [2] [3] [4] [5] [6] In spite of restricting HSCT to generally younger and healthier patients some series reported the incidence of cardiac complications as high as 43%, resulting in mortality rates of 9%. [6] [7] [8] [9] Cardiovascular events after myeloablative allogeneic HSCT are primarily associated with the use of high-dose CY in the conditioning regimen. [9] [10] [11] [12] [13] Dose reductions or replacement of high-dose CY with another immunosuppressive agent in conditioning regimens has led to a lower incidence of cardiac toxicity, but toxic deaths are still being reported. [11] [12] [13] [14] Reduced-intensity conditioning (RIC) was developed to allow patients with significant organ compromise or underlying comorbidities to receive allogeneic HSCT and this approach is now considered routine for these patients. Patients particularly at high risk for cardiac toxicity with myeloablative HSCT (ventricular ejection fractions of p45%) are considered candidates only for RIC. 5 Initial reports on agents used in RIC regimens demonstrated near absence of cardiac toxicities have been contradicted by more recent reports demonstrating that cardiac events do occur after RIC.
14-17 Nonetheless, the incidence and risk factors for cardiac events after RIC remain unknown. We therefore conducted an analysis in patients who underwent an RIC HSCT to determine the incidence of cardiac complications and to identify associated risk factors.
Materials and methods
We analyzed the charts of 278 patients who underwent RIC HSCT between July 2000 and July 2006 at two transplant centers. This study was conducted under institutional review board approval. All patients underwent pretransplant cardiac evaluation including echocardiogram and electrocardiogram (ECG). Patients were categorized as high risk according to either prior total anthracycline dose X400 mg/m 2 or an ejection fraction p45%. Post-HSCT cardiac events were defined as congestive heart failure, the development of an arrhythmia (confirmed by ECG) or myocardial infarction. Only one patient who developed cardiac toxicity had a prior history of a cardiac arrhythmia 4 years before transplant and was not on medications for rate control. All patients who developed a post-HSCT cardiac event underwent serial measurements of brain natriuretic peptide (BNP, normal 0-100 pg/ml), troponin (normal 0.00-0.29 ng/ml), creatine phosphokinase (CKMB, normal o26-180 U/l) and ECG until resolution of the clinical event.
Conditioning regimens
All patients were conditioned with BU 6.4 mg/kg, i.v., fludarabine 160 mg/m 2 , i.v. and 2 Gy of TBI, followed by allogeneic HSCT. Donors were HLA-matched relatives (n ¼ 150) or HLA-matched unrelated donors (n ¼ 128). The stem cell source was peripheral blood in all cases. GVHD prophylaxis consisted of tacrolimus, from day À3 until day 180 and mycophenolate mofetil from day 0 until day 30 in all patients.
Statistics
The relationship of anthracycline dose and left ventricle ejection fraction (LVEF) was examined by simple linear regression. Pre-transplant and post transplant LVEF was compared using the paired t-test. To compare LVEF in the two groups according to cumulative pre-transplant anthracycline dose or number of chemotherapy treatments, we used the unpaired t-test. Incidences of cardiac toxicity were compared using Fisher's exact test.
Results
Of 278 patients, 25 (9%) developed a cardiac event. Patient characteristics are described in Table 1 . The median age of patients who developed cardiac toxicity was 58 years, compared to a median age of 56 who did not develop cardiac toxicity. The median day of onset of the cardiac event was day 3 (range day À3 to þ 9). The cardiac event was an atrial arrhythmia in all 25 cases. The arrhythmias included atrial fibrillation in 16 patients (64%), atrial flutter in 7 patients (28%) and supraventricular tachycardia in 2 patients (8%). Associated with the cardiac event was elevation of both troponin level and CKMB in 12 (48%) patients. The BNP level (mean 679, range 488-989 pg/ml) was elevated in all patients that developed a cardiac event. Hemodynamic compromise (hypotension and or hypoxia) occurred in 19 (76%) of patients, and 15 (60%) required mechanical ventilation. All patients were successfully converted to normal sinus rhythm at a median of 2 days (range 0-4). However, recurrence of the cardiac complication occurred in 19 (76%) patients within 30 days of the initial event. Day 100 mortality was high in the patients with cardiac event at 10/25 (40%) compared to 28/278 (10%) in patients who did not develop a cardiac event (Figure 1) .
All patients who developed cardiac complications had a preexisting cardiac condition (25/25, 100% vs 12/253, 4%; P ¼ 0.001). The majority of the patients having a cardiac complication had received an anthracycline dose of 4400 mg/m 2 (19/25, 76% vs 12/253, 4%; P ¼ 0.003). A pre-transplant echocardiogram with an LVEF p45% was also strongly associated with the development of a cardiac toxicity (17/25, 68% vs 12/253, 4%; P ¼ 0.001). Age and donor type were not risk factors for the development of a cardiac complication.
Discussion
High-dose chemoradiotherapy is the major cause of organ toxicity in the myeloablative setting. Cardiac complications have been described in myeloablative HSCT with the majority of reported cardiac complications during HSCT attributed to the use of high-dose CY in the conditioning regimen. [11] [12] [13] [14] Known risk factors for cardiac complications include a reduced LVEF pre-transplant and previous exposure to anthracyclines. 13 Steinherz et al. observed an Figure 1 Outcomes of the 278 events that occurred in the patients who underwent reduced-intensity conditioning followed by hematopoietic stem cell transplant.
Cardiac complications in reduced-intensity SCT E Peres et al interaction between high-dose CY (4170 mg/kg) in the conditioning regimen and a prior cumulative exposure of 4100 mg/m 2 anthracycline dose leading to an increased risk of cardiac events in pediatric patients. 15, 18 Likewise, a recent report demonstrated that a cumulative dose of X250 mg/m 2 of anthracyclines before HSCT was an independent risk factor for the development of late congestive heart failure. [19] [20] [21] Thus, the contribution of previous anthracycline exposure, with its potential for progressive cardiac damage, to HD chemotherapy-associated cardiac toxicity is well established. [22] [23] [24] Therefore, it is not surprising that we identified prior anthracycline exposure and evidence of a damaged myocardium by a reduced LVEF as major risk factors for cardiac events after RIC regimens. Given the timing of cardiac events observed around the timing of the conditioning regimen, it appears probable that an interaction between the conditioning chemotherapy and a previously damaged myocardium is the precipitating event.
RIC regimens were developed to reduce the toxicities associated with myeloablative conditioning. 8 However, recent reports implicate melphalan doses of X140 mg/m 2 , a frequent component of RIC regimens, with atrial fibrillation. 16, 17, 25 All of our patients received fludarabine, which has also been recently described as a cause of cardiac dysfunction. [22] [23] [24] [25] [26] [27] These reports contradict the previously reported rarity of cardiotoxicity with these agents used in RIC conditioning. 14, 15 In addition, the combination of melphalan with fludarabine, a common RIC regimen, has recently been reported to cause severe cardiac toxicity with an incidence of about 2.5%. 11 These events have now been confirmed in three other reports, with an incidence of up to 14% and with variable outcomes ranging up to death. 17, [22] [23] [24] [25] [26] [27] In this study, we found an unexpectedly high rate of cardiac complications in patients with a risk factor (LVEF p45% and/or X400 mg/m 2 ). The patients who developed a cardiac complication frequently required intensive care management and their day 100 mortality of 40% was four times that observed in patients who did not develop a cardiac event. These results confirm the importance of a thorough cardiac evaluation before transplant. Patients with one or both of the identified risk factors should be counseled regarding their risk of a cardiac event and close monitoring of cardiac function, especially rhythm, during and shortly after conditioning chemotherapy appears advisable. There may be a potential for prevention in patients for whom allogeneic HSCT is recognized as part of the treatment plan from the time of diagnosis. For example, when medically appropriate alternatives may exist, such as avoidance of high-dose anthracyclines during induction, chemotherapy might reduce the risk of later cardiac complications. Furthermore, patients who might otherwise benefit from RIC HSCT may benefit from referral earlier in the disease course to avoid exposure to multiple courses of chemoradiotherapy. Because anthracyclines are among one of the most effective chemotherapeutic agents, exposure is unavoidable. Carvedilol is already used in treatment of anthracycline-induced cardiomyopathy. 28 However, recent data on the cardioprotectant carvedilol emphasize its protective effects in patients receiving anthracyclines to prevent anthracycline-induced cardiomyopathy. 20, 21, 28, 29 Prophylaxis with this agent should be considered during anthracycline therapy and it may be given to high-risk patients through RIC. 19 It may decrease myocardial consumption of oxygen through its chronotropic and inotropic properties and prevent both systolic and diastolic dysfunctions. [28] [29] [30] [31] There were limitations to this review and most likely the risk of cardiac toxicity was underestimated secondary to data collection limitations. Risk factors such as disease status, underlying disease and other comorbidities were not taken into consideration. Cardiac toxicity is multifactorial, and other precipitating events beyond preexisting cardiac disease are likely to be involved. A prospective trial would be able to identify additional risk factors and their relative risk stratification. 20 
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